About Us

THINK big. KEEP IT simple.

It was in late 2005 when a seemingly simple idea hit Charleston Laboratories founder and CEO Paul Bosse like a ton of bricks.

“As an active young man growing up in North Carolina, I experienced my fair share of pain. And unfortunately, whether it was from a serious sports-related injury or a more common and seemingly simple dental surgery, opioid-induced nausea and vomiting (OINV) has been a major obstacle in every single recovery.

“But it wasn’t until I started working in the pharmaceutical industry selling pain medication to healthcare professionals on a daily basis that I fully realized the unmet need caused by OINV. As it turns out…there are millions of patients just like me.

“I began thinking about the possible market for the drug that would become CL-108. I remembered my most-recent OINV nightmare after having my wisdom teeth removed, which was like every other previous experience. I was so incredibly nauseous from my opioid pain medication that I couldn’t even keep an anti-emetic down, so I knew the solution would have to be different than simply taking an anti-emetic with an opioid.

And that’s when it hit me. If I could formulate a medication with a differentiated release mechanism to immediately deliver an anti-nausea agent followed by a modified pain agent, I and others like me might finally get pain relief and recover.”

Currently, pain-related nausea and vomiting impose a significant burden on clinical care.

In fact, in a study of physician-patient encounters, nausea and/or vomiting were reported as a known reason for visiting the physician.1

The impact is even more stark when looking at patients who are high risk.

  • In patients receiving opioid analgesics for pain care, 40% experience opioid-induced nausea and vomiting.2
  • In patients recovering from surgery, 30% experience postoperative nausea and vomiting as an adverse effect of anesthesia.3
  • In patients who have received chemotherapy, 35% experience significant nausea and 19% experience vomiting.4
  • In patients suffering from acute migraine attacks, 73% develop nausea and 29% experience vomiting.5

In 2007, with the unmet need proven and the mission clear, Charleston Laboratories opened for business.

-Bar-

Today, Charleston Laboratories is the ONLY Acute Pain Care company equipped with a rich pipeline built with just one purpose – preventing and reducing nausea and vomiting at every level of pain.

References: 1. Britt H, Fahridin S. Presentations of nausea and vomiting. Aust Fam Physician. 2007;36(9):682-683. 2. Nicholson BD. Economic and clinical burden of opioid-induced nausea and vomiting. Postgrad Med. 2017;129(1):111-117. 3. Smith HS, Smith EJ, Smith BR. Postoperative nausea and vomiting. Ann Palliat Med. 2012;1(2):94-102. 4. Kottschade L, Novotny P, Lyss A, et al. Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance). Support Care Cancer. 2016;24(6):2661-2667. 5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine Study II. Headache. 2001;41(7):646-657.